We are live on !
Find out more
SL
Siren LLC Portfolio holdings
AUM
$4.94B
Turnover
27.78%
1-Year Est. Return
244.43%
This Fund
S&P 500
This Quarter Est. Return
+74.07%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.26B
AUM Growth
+$263M
(+13%)
Cap. Flow
+$192M
Cap. Flow % of AUM
Cap. Flow %
8.48%
Top 10 Holdings %
Top 10 Hldgs %
48.54%
Holding
134
New
22
Increased
21
Reduced
22
Closed
16
Avg Time Held
Equity + Options
0.2
years
Top 10 Avg Time Held
Equity + Options
0.2
years
Top 20 Avg Time Held
Equity + Options
0.2
years
Avg Time Held Equity only
0.2
years
Top 10 Avg Time Held Equity only
0.2
years
Top 20 Avg Time Held Equity only
0.2
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Septerna Inc
SEPN
|
+$52.1M |
| 2 |
Bicycle Therapeutics
BCYC
|
+$39.4M |
| 3 |
Apogee Therapeutics
APGE
|
+$38.1M |
| 4 |
Madrigal Pharmaceuticals
MDGL
|
+$35.4M |
| 5 |
NewAmsterdam Pharma
NAMS
|
+$25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$65.4M |
| 2 |
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
+$30.1M |
| 3 |
Wave Life Sciences
WVE
|
+$26.3M |
| 4 |
argenx
ARGX
|
+$16.8M |
| 5 |
Biohaven
BHVN
|
+$14.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.88% |
| 2 | Technology | 3.51% |
| 3 | Communication Services | 1.85% |
| 4 | Consumer Discretionary | 0.74% |
| 5 | Real Estate | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$4.86B
| $400M | 17.66% |
9,250,005
-2,009,433
| -18% | -$65.4M |
2024 Q3
1 quarter
|
|
2
BeOne Medicines Ltd
ONC
$41.7B
| $121M | 5.33% |
653,721
+90,407
| +16% | +$18.5M |
2024 Q3
1 quarter
|
|
3
Kymera Therapeutics
KYMR
$8.71B
| $119M | 5.28% |
2,969,733
| – | – |
2024 Q3
1 quarter
|
|
4
DELISTED
Apellis Pharmaceuticals
APLS
| $89.9M | 3.97% |
2,816,258
+649,034
| +30% | +$19.5M |
2024 Q3
1 quarter
|
|
5
DELISTED
Crinetics Pharmaceuticals
CRNX
| $82.3M | 3.64% |
1,609,652
+300,000
| +23% | +$16.8M |
2024 Q3
1 quarter
|
|
|
6
argenx
ARGX
$51.5B
| $70.8M | 3.13% |
115,045
-28,602
| -20% | -$16.8M |
2024 Q3
1 quarter
|
|
7
Bicara Therapeutics
BCAX
$1.11B
| $57M | 2.52% |
3,272,827
+200,000
| +7% | +$4.16M |
2024 Q3
1 quarter
|
|
8
Arrowhead Research
ARWR
$7.9B
| $54.6M | 2.41% |
2,901,681
+442,903
| +18% | +$9.12M |
2024 Q3
1 quarter
|
|
|
9
NewAmsterdam Pharma
NAMS
$2.37B
| $53.9M | 2.38% |
2,095,638
+1,175,074
| +128% | +$25M |
2024 Q3
1 quarter
|
|
|
10
Septerna Inc
SEPN
$1.7B
| $50.4M | 2.23% |
+2,202,514
| New | +$52.1M |
2024 Q4
0 quarters
|
|
|
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
| $50.3M | 2.22% |
3,004,677
-254,000
| -8% | -$4.21M |
2024 Q3
1 quarter
|
|
12
DELISTED
SpringWorks Therapeutics
SWTX
| $49.8M | 2.2% |
1,377,701
| – | – |
2024 Q3
1 quarter
|
|
13
Neumora Therapeutics
NMRA
$89M
| $46.6M | 2.06% |
4,396,100
+1,789,529
| +69% | +$21.4M |
2024 Q3
1 quarter
|
|
|
14
Wave Life Sciences
WVE
$617M
| $46.4M | 2.05% |
3,750,491
-1,970,681
| -34% | -$26.3M |
2024 Q3
1 quarter
|
|
15
Ascendis Pharma A/S
ASND
$14.8B
| $40.9M | 1.81% |
297,321
-50,600
| -15% | -$6.65M |
2024 Q3
1 quarter
|
|
|
16
Madrigal Pharmaceuticals
MDGL
$10.4B
| $38.9M | 1.72% |
+125,942
| New | +$35.4M |
2024 Q4
0 quarters
|
|
17
Taboola.com
TBLA
$929M
| $36.4M | 1.61% |
9,969,495
| – | – |
2024 Q3
1 quarter
|
|
|
18
DELISTED
Apogee Therapeutics
APGE
| $33.9M | 1.5% |
+747,325
| New | +$38.1M |
2024 Q4
0 quarters
|
|
19
DELISTED
Merus
MRUS
| $33M | 1.46% |
784,412
+102,211
| +15% | +$4.91M |
2024 Q3
1 quarter
|
|
|
RNAM
20
DELISTED
Avidity Biosciences
RNAM
| $32.8M | 1.45% |
1,127,295
-313,441
| -22% | -$13.1M |
2024 Q3
1 quarter
|
|
21
Vera Therapeutics
VERA
$2.01B
| $32.1M | 1.42% |
758,465
-79,463
| -9% | -$3.52M |
2024 Q3
1 quarter
|
|
22
Dyne Therapeutics
DYN
$2.66B
| $31.7M | 1.4% |
1,347,456
+212,792
| +19% | +$6.29M |
2024 Q3
1 quarter
|
|
23
Xenon Pharmaceuticals
XENE
$3.24B
| $29.2M | 1.29% |
743,769
| – | – |
2024 Q3
1 quarter
|
|
24
Lexicon Pharmaceuticals
LXRX
$676M
| $28.8M | 1.27% |
38,918,903
| – | – |
2024 Q3
1 quarter
|
|
|
25
Bicycle Therapeutics
BCYC
$242M
| $25.8M | 1.14% |
+1,839,398
| New | +$39.4M |
2024 Q4
0 quarters
|
|
Similar funds
FC
Siren LLC's Q4 2024 Portfolio in Review
As of Q4 2024, Siren LLC held 134 positions worth $2.26B, up 13% from $2B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Siren LLC deployed $192M of net new capital in Q4 2024, opening 22 new positions and adding to 21 existing holdings. Its largest new stake was Septerna Inc: 2,202,514 shares worth $50.4M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Scholar Rock, an estimated $65.4M trimmed.
- Siren LLC's largest Q4 2024 buy was Septerna Inc: 2,202,514 shares worth $50.4M.
- Siren LLC added most to NewAmsterdam Pharma in Q4 2024, an estimated $25M increase.
- Siren LLC's biggest Q4 2024 reduction was Scholar Rock, cutting an estimated $65.4M.
- Siren LLC fully exited Longboard Pharmaceuticals, Inc. Common Stock in Q4 2024, selling an estimated $30.1M.
- Siren LLC's ten largest holdings make up 49% of its $2.26B portfolio in Q4 2024.
- Siren LLC opened 22 new positions and closed 16 in Q4 2024.
- Siren LLC's portfolio value rose 13% quarter-over-quarter to $2.26B.
Based on Siren LLC's 13F filing for Q4 2024, filed 14 Feb 2025.